S R Friedman1, T Perlis, D C Des Jarlais. 1. National Development and Research Institutes, Inc, Two World Trade Center, 16th Fl, New York, NY 10048, USA. sam.friedman@ndri.org
Abstract
OBJECTIVES: This study sought to assess relations of laws prohibiting over-the-counter syringe sales (anti-OTC laws) to population prevalence of injection drug users and HIV prevalence or incidence among 96 US metropolitan areas. METHODS: A cross-sectional analysis was used. RESULTS: Metropolitan areas with anti-OTC laws had a higher mean HIV prevalence (13.8% vs 6.7%) than other metropolitan areas (pseudo-P < .001). In 83 metropolitan areas with HIV prevalence of less than 20%, anti-OTC laws were associated with HIV incidence rates of 1% or greater (pseudo-P < .001). Population proportions of injection drug users did not vary by presence of anti-OTC laws. CONCLUSIONS: Anti-OTC laws are not associated with lower population proportions of injection drug users. Laws restricting syringe access are associated with HIV transmission and should be repealed.
OBJECTIVES: This study sought to assess relations of laws prohibiting over-the-counter syringe sales (anti-OTC laws) to population prevalence of injection drug users and HIV prevalence or incidence among 96 US metropolitan areas. METHODS: A cross-sectional analysis was used. RESULTS: Metropolitan areas with anti-OTC laws had a higher mean HIV prevalence (13.8% vs 6.7%) than other metropolitan areas (pseudo-P < .001). In 83 metropolitan areas with HIV prevalence of less than 20%, anti-OTC laws were associated with HIV incidence rates of 1% or greater (pseudo-P < .001). Population proportions of injection drug users did not vary by presence of anti-OTC laws. CONCLUSIONS: Anti-OTC laws are not associated with lower population proportions of injection drug users. Laws restricting syringe access are associated with HIV transmission and should be repealed.
Authors: D C Des Jarlais; S R Friedman; D M Novick; J L Sotheran; P Thomas; S R Yancovitz; D Mildvan; J Weber; M J Kreek; R Maslansky Journal: JAMA Date: 1989-02-17 Impact factor: 56.272
Authors: S L Groseclose; B Weinstein; T S Jones; L A Valleroy; L J Fehrs; W J Kassler Journal: J Acquir Immune Defic Syndr Hum Retrovirol Date: 1995-09-01
Authors: D Caussy; S H Weiss; W A Blattner; J French; K P Cantor; H Ginzburg; R Altman; J J Goedert Journal: AIDS Res Hum Retroviruses Date: 1990-12 Impact factor: 2.205
Authors: Scott Burris; Kim M Blankenship; Martin Donoghoe; Susan Sherman; Jon S Vernick; Patricia Case; Zita Lazzarini; Stephen Koester Journal: Milbank Q Date: 2004 Impact factor: 4.911
Authors: Hannah L F Cooper; Brooke West; Sabriya Linton; Josalin Hunter-Jones; Maria Zlotorzynska; Ron Stall; Mary E Wolfe; Leslie Williams; H Irene Hall; Charles Cleland; Barbara Tempalski; Samuel R Friedman Journal: Am J Public Health Date: 2015-12-21 Impact factor: 9.308
Authors: Samuel R Friedman; Spencer Lieb; Barbara Tempalski; Hannah Cooper; Marie Keem; Risa Friedman; Peter L Flom Journal: J Urban Health Date: 2005-07-13 Impact factor: 3.671
Authors: Victoria Frye; Mary H Latka; Beryl Koblin; Perry N Halkitis; Sara Putnam; Sandro Galea; David Vlahov Journal: J Urban Health Date: 2006-03 Impact factor: 3.671
Authors: Barbara Tempalski; Peter L Flom; Samuel R Friedman; Don C Des Jarlais; Judith J Friedman; Courtney McKnight; Risa Friedman Journal: Am J Public Health Date: 2007-01-31 Impact factor: 9.308
Authors: Samuel R Friedman; Brooke S West; Barbara Tempalski; Cory M Morton; Charles M Cleland; Don C Des Jarlais; H Irene Hall; Hannah L F Cooper Journal: Ann Epidemiol Date: 2014-01-24 Impact factor: 3.797
Authors: Samuel R Friedman; Barbara Tempalski; Joanne E Brady; Brooke S West; Enrique R Pouget; Leslie D Williams; Don C Des Jarlais; Hannah L F Cooper Journal: Int J Drug Policy Date: 2016-03-11